Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 10, 2021

View Archived Issues

Allena initiates two phase II trials of its engineered urate oxidase, ALLN-346

TRACON presents safety data review results for ENVASARC pivotal trial of envafolimab

First patient dosed in phase Ib/II study of AVB-500 in pancreatic adenocarcinoma

Korea Institute of Science and Technology identifies TNK2/MAP4K2 inhibitors

Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine patent ATR kinase inhibitors

New PIN1 inhibitors discovered at Pimedbio, DGMIF

Gruenenthal divulges glucocorticoid receptor modulators

Phase II MERIT study of AXS-05 achieves primary and key secondary endpoints

Trillium initiates dosing of patients with TP53-mutated AML in phase Ib/II study of TTI-622

Otsuka receives a grant for phase II study of OPC-167832 plus delamanid and bedaquiline

NRx initiates phase IIb study of BriLife COVID-19 vaccine in Georgia

SPNS2 inhibition may be useful in treating autoimmune disease

Sorrento presents development of multivalent mRNA COVID-19 vaccine

Emory University tests yeast-expressed SARS-CoV-2-specific RBD-based vaccine in rhesus macaques

AAV2-hAADC gene therapy shows safety and efficacy in children with AADC deficiency

Stress hormones affect brain plasticity via distinct mechanisms

Ohio State University describes looped proteins comprising cell-penetrating peptides

First patient dosed in phase I study of APL-102

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...